Bayer's KERENDIA (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026
September 17, 2026
WHIPPANY, New Jersey, Sept. 17 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:
* * *
Bayer's KERENDIA(r) (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
*
KERENDIA(r) (finerenone), a non-steroidal mineralocorticoid receptor antagonis . . .
* * *
Bayer's KERENDIA(r) (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
*
KERENDIA(r) (finerenone), a non-steroidal mineralocorticoid receptor antagonis . . .